Patents by Inventor Grant MacLean

Grant MacLean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Underwater power saving mechanism for use in an communication network
    Patent number: 10945211
    Abstract: An underwater communications network comprising a plurality of communication nodes operable to wirelessly communicate with at least one other node in the network, each node having a transceiver and an observation mechanism wherein the observation mechanism is operable to monitor signals received by the transceiver and upon reception of a first predetermined tone the observation mechanism outputs a signal operable to adjust the node from a passive operation mode to an active operation mode. Each node can be a discreet underwater device.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: March 9, 2021
    Inventors: Brendan Peter Hyland, Grant MacLean
  • UNDERWATER POWER SAVING MECHANISM FOR USE IN AN COMMUNICATION NETWORK
    Publication number: 20160007293
    Abstract: An underwater communications network comprising a plurality of communication nodes operable to wirelessly communicate with at least one other node in the network, each node having a transceiver and an observation mechanism wherein the observation mechanism is operable to monitor signals received by the transceiver and upon reception of a first predetermined tone the observation mechanism outputs a signal operable to adjust the node from a passive operation mode to an active operation mode. Each node can be a discreet underwater device.
    Type: Application
    Filed: February 25, 2014
    Publication date: January 7, 2016
    Inventors: Brendan Peter HYLAND, Grant MACLEAN
  • Combination Therapy for Cancer
    Publication number: 20080081045
    Abstract: Anti-hormonal (anti-estrogenic steroid) therapy and immunotherapy are used in combination to treat breast cancer. The preferred immunotherapeutic agent is an immunogen, preferably comprising sialyl-Tn, and more preferably is a sialyl-Tn/KLH conjugate.
    Type: Application
    Filed: October 14, 2004
    Publication date: April 3, 2008
    Applicant: BIOMIRA, INC.
    Inventors: Mairead Kehoe-Whistance, Grant MacLean
  • Carcinoma-marking monoclonal antibodies elicited with synthetic Asialo-GM1 antigen
    Patent number: 5455332
    Abstract: Monoclonal antibodies produced after immunization with a synthetic antigen bearing the structure Gal (beta 1-3) GalNac beta-glycosidically linked to a carrier moiety are useful as carcinoma markers. Radioimmunoimaging agents are described in which such antibodies are tagged with radiometals or radiohalogens. Radiolabeled monoclonal antibody 155H.7, elicited by this antigen, rapidly localizes and persists in tumor tissues, demonstrating its utility as a tumor imaging agent.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: October 3, 1995
    Assignee: Biomira, Inc.
    Inventors: Connie J. Turner, Bryan M. Longenecker, David J. Willans, Antoine A. Noujaim, Grant MacLean